Leukemia Research
Volume 26, Issue 8 , Pages 757-763 , August 2002

Engineered fusion hybrid vaccine of IL-4 gene-modified myeloma and relative mature dendritic cells enhances antitumor immunity

  • Yongqing Liu

      Affiliations

    • Research Unit, Saskatchewan Cancer Agency, Departments of Oncology and Pathology, College of Medicine, University of Saskatchewan, 20 Campus Drive, Saskatoon, Saskatchewan, Canada S7N 4H4
    • ,
  • Weidong Zhang

      Affiliations

    • Research Unit, Saskatchewan Cancer Agency, Departments of Oncology and Pathology, College of Medicine, University of Saskatchewan, 20 Campus Drive, Saskatoon, Saskatchewan, Canada S7N 4H4
    • ,
  • Tim Chan

      Affiliations

    • Research Unit, Saskatchewan Cancer Agency, Departments of Oncology and Pathology, College of Medicine, University of Saskatchewan, 20 Campus Drive, Saskatoon, Saskatchewan, Canada S7N 4H4
    • ,
  • Anurag Saxena

      Affiliations

    • Department of Pathology, College of Medicine, University of Saskatchewan, 103 Hospital Drive, Saskatoon, Saskatchewan, Canada S7N 0W8
    • ,
  • Jim Xiang

      Affiliations

    • Research Unit, Saskatchewan Cancer Agency, Departments of Oncology and Pathology, College of Medicine, University of Saskatchewan, 20 Campus Drive, Saskatoon, Saskatchewan, Canada S7N 4H4
    • Corresponding Author InformationCorresponding author. Tel.: +1-306-655-2917; fax: +1-306-655-2635

Received 17 September 2001 ,Accepted 4 December 2001.

References 

  1. Melief D. Tumor eradication by adoptive transfer of cytotoxic T lymphocytes. Adv. Cancer Res. 1992;58:143–175
  2. Townsend A, Trowsdale A. The transporters associated with antigen presentation. Semin. Cell Biol. 1993;4:53–61
  3. Yewdell J, Bennink J. Cell biology of antigen processing and presentation to MHC class I molecule restricted T lymphocytes. Adv. Immunol. 1992;52:1–123
  4. Chen L, Ashe S, Brady W, Hellstrom K. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecule CD28 and CTLA-4. Cell. 1992;71:1093–1102
  5. Chen H, Gabrilovich D, Tampe R, Girgis K, Nadaf S, Carbone D. A functional defective allele of TAP1 results in loss of MHC class I antigen presentation in a human lung cancer. Nature Genet. 1996;13:210–213
  6. Armstrong T, Clements V, Martin B, Ting J, Ostrand-Rosenberg S. Major histocompatibility complex class II-transfected tumor cells present endogenous antigen and are potent inducers of tumor-specific immunity. PNAS. 1997;94:6886–6891
  7. Hock H, Dorsch M, Kunzendorf U, Qin Z, Diamantstein T, Blankenstein T. Mechanisms of rejection induced by tumor cell-targeted gene transfer of interleukin-2, interleukine-4, interleukin-7, tumor necrosis factor and interferon gamma. PNAS. 1993;90:2774–2778
  8. Maric M, Liu Y. Strong cytotoxic T lymphocyte responses to a macrophage inflammatory protein 1α-expressing tumor: linkage between inflammation and specific immunity. Cancer Res. 1999;59:5549–5553
  9. Huang A, Golumbec P, Ahmadzadeh M, Jaffe E, Pardoll D, Levitsky H. Role of bone marrow-derived cells in presenting MHC class I restricted tumor antigens. Science. 1994;264:961–965
  10. Mayordomo J, Zorina T, Storkus W, Zitvogel L, Celluzzi C, Falo L, et al.  Bone marrow-derived dendritic cells pulsed with synthetic tumor peptide elicit protective and therapeutic antitumor immunity. Nature Med. 1995;1:1297–1302
  11. Asheley D, Faiola B, Nair S, Hale L, Bigner D, Gilbao E. Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induced antitumor immunity against central nervous system tumors. J. Exp. Med. 1997;186:1177–1182
  12. Nestle F, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, et al.  Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nature Med. 1998;4:328–332
  13. Labeur M, Roters B, Pers B, Mehling A, Luger T, Schwarz T, et al.  Generation of tumor immunity by bone marrow-derived dendritic cells correlates with dendritic cell maturation stage. J. Immunol. 1999;162:168–175
  14. Guo Y, Wu M, Chen H, Wang X, Liu G, Li G, et al.  Effective tumor vaccine generated by fusion of hepatoma cells with activated B cells. Science. 1994;263:518–520
  15. Gong J, Chen D, Kashiwaba M, Kufe D. Induction of antitumor activity by immunization with fusion of dendritic and carcinoma cells. Nature Med. 1997;3:558–560
  16. Gong J, Chen D, Kashiwaba M, Li Y, Chen L, Takeuchi H, et al.  Reversal of tolerance to human MUC1 antigen in MUC1 transgenic mice immunized with fusions of dendritic and carcinoma cells. PNAS. 1998;95:6279–6283
  17. Kugler A, Stuhler G, Walden P, Zoller G, Zobywalski A, Brossart P, et al.  Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nature Med. 2000;6:332–336
  18. Bender A, Sapp M, Schuler G, Steinman R, Bhardwaj N. Improved methods for the genration of dendritic cells from nonproliferating progenitors in human blood. J. Immunol. Methods. 1996;196:121–135
  19. Caron G, Delneste Y, Roelandts E, Duez C, Herbault N, Magistrelli G, et al.  Histamine induces CD86 expression and chemokine production by human immature dendritic cells. J. Immunol. 2001;166:6000–6006
  20. Song W, Kong H, Carpenter H, Torii H, Granstein R, Rafii S, et al.  Dendritic cells genetically modified with adenovirus vector encoding the cDNA for a model antigen induce protective and therapeutic antitumor immunity. J. Exp. Med. 1997;186:1247–1256
  21. Lutz M, Suri R, Niimi M, Ogilvie A, Kukutsch N, Robner S, et al.  Immature dendritic cells generated with low doses of GM-CSF in the absence of IL-4 are maturation resistant and prolong allograft survival in vivo. Eur. J. Immunol. 2000;30:1813–1822
  22. Xiang J, Moyana T. Regression of engineered tumor cells secreting cytokines is related to a shift in host cytokine profile from type 2 to type 1. J. Interferon Cytokine Res. 2000;20:349–354
  23. Curiel-Lewandrowski C, Mahnke K, Labeur M, Roters B, Schmidt W, Granstein R, et al.  Transfection of immature murine bone marrow-derived dendritic cells with granulocyte-macrophage colony-stimulating factor gene potently enhances their in vivo antigen-presenting capacity. J. Immunol. 1999;163:174–183
  24. Wang J, Saffold S, Cao X, Krauss J, Chen W. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines. J. Immunol. 1998;161:5516–5524
  25. Xiang J, Moyana T. Regression of engineered tumor cells secreting cytokines ia related to a shift in host cytokine profile from type 2 to type 1. J. Interferon Cytokine Res. 2000;20:349–354
  26. Inaba K, Young J, Steiman R. Direct activation of CD8 cytotoxic T lymphocytes by dendritic cells. J. Exp. Med. 1987;166:182–194
  27. Schuler G, Koch F, Heufler C, Kampgen E, Topar G, Romani N. Murine epidermal Langerhans cells as a model to study tissue dendritic cells. Adv. Exp. Med. Biol. 1993;329:243–249
  28. Steinman R, Bancherear J. Dendritic cells and the control of immunity. Nature. 1998;392:245–252
  29. Steinman R, Witmer-Pack M, Inaba K. Dendritic cells: antigen presentation, accessory function and clinical relevance. Adv. Exp. Med. Biol. 1993;329:1–9
  30. Cella M, Sallusto F, Lanzavecchia A. Origin, maturation and antigen presenting function of dendritic cells. Curr. Opin. Immunol. 1997;9:10–16
  31. Jonuleit H, Knop J, Enk A. Cytokines and their effects on maturation, differentiation and migration of dendritic cells. Arch. Dermatol. Res. 1996;289:1–8
  32. Chen Z, Moyana T, Saxena A, Warrington R, Jia Z, Xiang J. Efficient antitumor immunity derived from enhanced maturation of dendritic cells which had phagocytosed apoptotic tumor cells. Int. J. Cancer. 2001;93:539–548
  33. Menetrier-Caux C, Thomachot M, Alberti L, Montmain G, Blay J. IL-4 prevents the blockade of dendritic cell differentiation induced by tumor cells. Cancer Res. 2001;61:3096–3104
  34. Swain S, Huston G, Tonkonogy S, Weinberg A. Transforming growth factor and IL-4 cause helper T cell precursors to develop into distinct effector cells that differ in lymphokine secretion pattern and cell surface phenotype. J. Immunol. 1991;147:2991–3000
  35. Kalinski P, Smits H, Schuitemaker J, Vieira P, Eijk M, Jong E, et al.  IL-4 is a mediator of IL-12p70 induction by human Th2 cells: reversal of polerized Th2 phenotype by dendritic cells. J. Immunol. 2000;165:1877–1881
  36. Stoppacciaro A, Paglia P, Lombardi L, Parmiani G, Baroni C, Colombo M. Genetic modification of a carcinoma with IL-4 gene increases the influx of dendritic cells relative to other cytokines. Eur. J. Immunol. 1997;27:2375–2382
  37. Cayeux S, Richter G, Noffz G, Dorken B, Blankenstein T. Influence of gene-modified (IL-7, IL-4 and B7) tumor cell vaccines on tumor antigen presentation. J. Immunol. 1997;158:2834–2841

PII: S0145-2126(02)00002-4

Leukemia Research
Volume 26, Issue 8 , Pages 757-763 , August 2002

Article Tools

* Image Usage & Resolution